Monday 8 December 2014

Improved Survival in Aggressive Acute Myeloid Leukemia: Study

Combination of an existing agent cytarabine with a newer compound, vosaroxin, has been proven beneficial for patients who relapse in their battle with acute myeloid leukemia, found in a phase three study. The study, led by Farhad Ravandi, M.D, professor of medicine, department of leukemia at The University of Texas MD Anderson Cancer Center, demonstrated increased survival rates, particularly in AML patients over age 60. Ravandi's study results were ...

via Medindia Health News More READ

No comments:

Post a Comment